Certara, Inc. Leadership

Jon Resnick has served as Chief Executive Officer of Certara since January 1, 2026 and joined the Board of Directors as a Class III director in January 2026. Before joining Certara he spent more than two decades at IQVIA Holdings, most recently as President of its U.S. and Canada regional business from July 2019 through December 2025, and earlier as President of IQVIA's Real World Solutions unit following the 2016 IMS Health/Quintiles merger. He began his career on the U.S. Senate Committee on Finance advising on healthcare policy, and holds an MBA from Northwestern's Kellogg School of Management and a B.A. from Union College.

James Cashman III has served as a Certara director since 2018 and as Chairman of the Board since December 1, 2021. He was Chief Executive Officer of engineering-simulation software company ANSYS, Inc. from February 2000 to December 2016 and served as its Chair from January 2017 until retiring in April 2019. He previously served on the board of National Instruments Corporation and holds BSME, MSME and MBA degrees from the University of Cincinnati.

Stephen McLean has served on Certara's board since 2013 and is an Arsenal Capital Partners designee under the company's Stockholders Agreement, serving on the Nominating and Corporate Governance Committee. He has been a Partner at Arsenal Capital Partners, a healthcare- and industrial-focused private equity firm, since 2010, and co-founded Merrill Lynch Capital Partners in 1984. He currently sits on the boards of private companies including WCG Clinical, CellCarta and 3DR Labs, and holds a B.S. in Economics and an MBA from the Wharton School of the University of Pennsylvania.

David Spaight has served as a Certara director since 2022 as an Arsenal Capital Partners designee and sits on the Compensation Committee. He has been an Operating Partner at Arsenal Capital Partners since 2016 and previously served as Chairman and CEO of contract research organization WIL Research from 2010 to 2016 and as President of MDS Pharma Services. He has held executive roles at Fisher Scientific and PerkinElmer, chaired the Association of Clinical Research Organizations, and holds a B.S. and an MBA from the University of Michigan.

Nancy Killefer has served as a Certara director since 2021 and chairs the Compensation Committee while also serving on the Nominating and Corporate Governance Committee. She spent more than 15 years as a Senior Partner at McKinsey & Company, leading its Washington, D.C. office and Public Sector Practice, and served as Assistant Secretary for Management, CFO and COO of the U.S. Department of the Treasury from 1997 to 2000. She currently serves on the boards of Cardinal Health and Meta Platforms and holds a B.A. from Vassar College and an M.S. in Management from MIT.

Eran Broshy has served as a Certara director since 2022, sitting on the Audit Committee and chairing the Nominating and Corporate Governance Committee. He was CEO of Syneos Health (formerly inVentiv Health) until 2008 and its Chair until 2010, and earlier spent roughly 15 years at The Boston Consulting Group leading its Americas healthcare practice. He serves on the board of Theravance Biopharma, has partnered with private equity firms including EQT and Nordic Capital, and holds a B.S. from MIT, an M.S. from Stanford and an MBA from Harvard.

John Reynders, PhD, has served as a Certara director since 2024 and sits on the Audit Committee. He is Chief Data Scientist and a Venture Partner at Iaso Ventures and founder and CEO of Latent Strategies, LLC, and previously served as Chief Data Sciences Officer of Neumora Therapeutics and as founding Chief Information Officer of Moderna Therapeutics. He has held senior data-science and informatics roles at Alexion, AstraZeneca and Johnson & Johnson and holds a B.S. from Rensselaer Polytechnic Institute, a Ph.D. from Princeton and an MBA from Northwestern's Kellogg School.

Matthew Walsh has served as a Certara director since 2020 and chairs the Audit Committee. He has been Executive Vice President and CFO of Organon & Co. since June 2020, was CFO of Allergan plc from 2018 until its 2020 acquisition by AbbVie, and served as CFO of Catalent, Inc. from 2008 to 2018. He holds a B.S. in Chemical Engineering and an MBA, both from Cornell University.

Arjun Bedi joined Certara's board as a Class III director in February 2026 and serves on the Audit Committee. He has been a Senior Strategic Advisor at Accenture plc since September 2024, previously served on Accenture's Global Management Committee from 2020 to 2024, and chaired its Strategic Client Portfolio, with deep experience leading life-sciences and healthcare transformations. He is a founder of the Health & Life Sciences CEO Forum and holds a B.A. in Economics from the University of Delhi and an MBA from Temple University.

Cynthia Collins has served as a Certara director since 2021 and sits on the Audit Committee; she provided notice of her resignation effective upon the election of the Class III directors at the May 14, 2026 annual meeting. She has been CEO of several pharmaceutical and biotechnology companies, most recently Editas Medicine, and earlier Human Longevity, GenVec and Sequoia Pharmaceuticals, with senior roles at GE Healthcare, Beckman Coulter and Baxter Healthcare. She has served on the boards of Codexis, DermTech and MaxCyte.

Rosemary Crane served as a Certara director from 2022 and on the Compensation Committee; she was not renominated for the Class III slate and her service concluded at the May 14, 2026 annual meeting. She was President and CEO of MELA Sciences and of Epocrates, held senior executive positions at Johnson & Johnson from 2002 to 2008 and at Bristol-Myers Squibb from 1982 to 2002, and has served on the board of Teva Pharmaceutical Industries. She holds an MBA from Kent State University and a B.A. from the State University of New York.

William F. Feehery, Ph.D., served as Chief Executive Officer of Certara from June 2019 until the end of 2025, when he entered a separation and consulting agreement and was succeeded by Jon Resnick effective January 1, 2026; he also served on the board from 2019. Before Certara he was President of DuPont Industrial Biosciences from 2013 to 2019, having joined DuPont in 2002, with earlier experience in venture capital and at The Boston Consulting Group. He holds a Ph.D. in chemical engineering and an MBA from MIT, was a Churchill Scholar at Cambridge University, and has served on the board of West Pharmaceutical Services.

John E. Gallagher III served as Certara's Senior Vice President and Chief Financial Officer from April 2023 and was a named executive officer for fiscal 2025. He was previously CFO of Cue Health from March 2021 to March 2023 and spent nearly a decade at Becton, Dickinson & Co., including as SVP and CFO of its Medical Segment and Treasurer and as SVP, Controller and Chief Accounting Officer. Earlier he held finance roles at NBCUniversal, General Electric and Ford Motor Company.

Robert A. Aspbury, Ph.D., has served as President of Certara Predictive Technologies (formerly the Scientific Software and Simcyp division) since January 2020, after serving as Chief Operating Officer of Simcyp from April to December 2019. Before joining Certara he was Vice President of Strategic Solutions, Biosimilars at Covance and held multiple senior commercial and finance roles there over more than 17 years. He is a qualified chartered accountant and holds a doctorate from the University of Liverpool.

Leif E. Pedersen served as Certara's President and Chief Commercial Officer from August 2023, after serving as President of Software from September 2020 to August 2023, and was a named executive officer for fiscal 2025. Before Certara he was a Senior Operating Partner at SymphonyAI, CEO of BIOVIA (a division of Dassault Systemes) from 2017 to 2019, and Executive Vice President at Innovative Interfaces. His career centers on commercial leadership of scientific and enterprise software businesses.

Adrian K. McKemey, Ph.D., has served as President of Certara Drug Development Solutions since March 2025. Before joining Certara he was Head of Enterprise Transformation at IQVIA from 2022 to 2025 and, from 2016 to 2022, Senior Vice President and Head of R&D Strategy Solutions at IQVIA (formerly Quintiles), and earlier a Principal in the Life Sciences practice at The Boston Consulting Group. He holds a B.S. with First Class honors and a Ph.D. in high energy nuclear particle physics from the University of London.